Successfully commercializing microbiome-based diagnostics, therapeutics, adjunct therapies and direct-to-consumer services and products.
The new paradigm of treatment: Understanding the relationship between ecology and medicine in unlocking the potential of the microbiome

- What is the current state of the field and how have new techniques in molecular biology enabled us to probe the microbiome and better understand its diversity and biological significance?
- When dealing with living organisms- How does microbial ecology differ from classical drug therapies, and classical medical statistics?
- What areas have we seen greatest progress and how do we avoid overselling microbiome potential and current state before we have solid evidence of translational capacity?

Jack Gilbert, Faculty Director, The Microbiome Center Professor, Department of Surgery, The University of Chicago Senior Scientist (Adjunct), the Marine Biological Laboratory, Group Leader in Microbial Ecology, Argonne National Laboratory
The study of Microbiome is rapidly evolving into both viable treatments and associated commercial opportunities. The inaugural Microbiome World Congress Americas 2017 will bring together leading pharma, biotechs, academic researchers, and their partners to Washington DC in order to discuss how to successfully commercialize microbiome-based diagnostics, therapeutics, adjunct therapies and direct-to-consumer services and products.

With leading researchers like Jack Gilbert of The University of Chicago, and Elaine Hsiao of UCLA, alongside the FDA and leading pharma and biotechs such as Janssen, Pfizer, Seres Therapeutics and Enterome, this will be a forum for the entire community to come together to learn, network and create the partnerships necessary to develop microbiome-based diagnostics and therapies. At the same time, academic researchers will gain key insights into how to develop and commercialize their research.

Throughout our congress we have assembled leaders from academia to pharma to pinpoint leading issues in regulation, bioinformatics, and financing of microbiome therapies. Our cutting edge Pitch and Partner program will serve as a platform to biotechs looking for funding and partnerships, highlighting promising microbiome investment opportunities for investors and big pharma.

Furthermore, our Microbiome World Congress Americas is co-located with the industry leading Precision Medicine Congress USA, to find synergy in this next generation of creating truly personalized treatments that will change the future of medicine and health as we know it.

The earlier you book, the more you save! Visit www.terrapinn.com/microbiomeUS
This landmark congress is bringing together some of microbiomes most important pioneers – from Paul Carlson Jr, the FDA’s first co-chair on FMT, to Elaine Hsiao, whose influential work in the gut-brain exis catapulted her into the 2014 Forbes “30 Under 30 in Science and Healthcare” list. These luminaries are gathering at the World Microbiome Congress to tell the world how they got there – and where they’re going next.

SCIENCE

Paul E. Carlson Jr., Ph.D., Principal investigator, Laboratory of Mucosal Pathogens and Cellular Immunology, CBER/OVRR, U.S. Food and Drug Administration

Elaine Hsiao, Ph.D., Principal Investigator, Hsiao Lab, UCLA

Marina R. Walther-Antonio, Ph.D., Assistant Professor of Surgery, Mayo Clinic

Jose C. Clemente, Ph.D., Assistant Professor, Department of Genetics and Genomic Sciences and the Immunology Institute at the Icahn School of Medicine at Mount Sinai

Suzanne Devkota, Ph.D., Assistant Professor, Director Microbiome Research at F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, David Geffen School of Medicine, UCLA

Mehrdad Yazdani, Ph.D., Machine Learning and Data Scientist, Open Medicine Institute, California Institute for Telecommunications and Information Technology, UC San Diego

COMMERCIAL

Nikola Trbovic, Ph.D., Director R&D Technology Strategy, Pfizer

Carrie (McManus) Brodmerkel, Head, Immunology Biomarkers, Immunology Therapeutic Area, Janssen R&D

Jim Brown, B.Sc., M.Sc., Ph.D., Director, Computational Biology, Senior Fellow, GlaxoSmithKline

Matt Henn, PhD, Senior VP, Head of Drug Discovery and Bioinformatics, Seres Therapeutics

Rodolphe Clerval, Chief Business Officer, Enterome Bioscience

Alex Scheeler, Senior Regulatory Affairs Associate, OpenBiome

Spearheading the nascent commercialization of microbiome are our expert speakers from established pharma and the newest, most cutting-edge biotechs. Pfizer, Janssen, and GSK will show attendees how to maximize the therapeutic potential of emerging platforms. On the biotech side, speakers range from Rodolphe Clerval who brought finance and microbiome together, to Matt Henn, whose expertise has made Seres Therapeutics one of Microbiome’s biggest early players.
<table>
<thead>
<tr>
<th>Name</th>
<th>Title &amp; Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nikola Trbovic</td>
<td>Director R&amp;D Technology Strategy, Pfizer</td>
</tr>
<tr>
<td>Jim Brown</td>
<td>Director in Computational Biology, GlaxoSmithKline</td>
</tr>
<tr>
<td>Micah Mackison</td>
<td>VP Corporate Development and Strategy, Assembly Biosciences</td>
</tr>
<tr>
<td>Alex Scheeler</td>
<td>Senior Regulatory Affairs Associate, OpenBiome</td>
</tr>
<tr>
<td>Travis Whitfill</td>
<td>Co-Founder, Azitra Inc.</td>
</tr>
<tr>
<td>Michael Kaleko</td>
<td>Senior Vice President, Research &amp; Development, Synthetic Biologics</td>
</tr>
<tr>
<td>Carrie (McManus)</td>
<td>Head, Immunology Biomarkers, Immunology Therapeutic Area, Janssen R&amp;D</td>
</tr>
<tr>
<td>Matt Henn</td>
<td>Sr. VP, Head of Drug Discovery and Bioinformatics, Seres Therapeutics</td>
</tr>
<tr>
<td>Aoife Brennan</td>
<td>Chief Medical Officer, Synlogic</td>
</tr>
<tr>
<td>Nikole Kimes</td>
<td>Founder, Vice President, Siolta Therapeutics</td>
</tr>
<tr>
<td>Nikole Kimes</td>
<td>Founder, Vice President, Siolta Therapeutics</td>
</tr>
<tr>
<td>Jonathan Scheiman</td>
<td>Co-Founder CEO, FitBiomics Inc.</td>
</tr>
<tr>
<td>Kathleen Basmadjian</td>
<td>Sr Director, Global Regulatory Policy &amp; Intelligence, Global Regulatory Affairs, Janssen R&amp;D</td>
</tr>
<tr>
<td>Rodolphe Clerval</td>
<td>Chief Business Officer, Enterome</td>
</tr>
<tr>
<td>Henry Rath</td>
<td>VP Business Development, Seres Therapeutics</td>
</tr>
<tr>
<td>James Mutamba</td>
<td>Co-Founder, Commense Health</td>
</tr>
<tr>
<td>Barry Goldman</td>
<td>Vice President, Discovery, Indigo Agriculture</td>
</tr>
<tr>
<td>Lilly Ting</td>
<td>Associate, PureTech Health, Head of Science, Commence Health</td>
</tr>
</tbody>
</table>
2017 Speakers

**RESEARCH LEADERS**

Jack Gilbert  
Faculty Director, The Microbiome Center

Elaine Hsiao  
Assistant Professor, Department of Integrative Biology & Physiology, UCLA

Andreas Kogelnik  
Founder and CEO, Open Medicine Institute

Marina R. Walther-Antonio  
Assistant Professor of Surgery, Mayo Clinic

Jose C. Clemente  
Assistant Professor, Department of Genetics and Genomic Sciences and the Immunology Institute at the Icahn School of Medicine at Mount Sinai

Lynn M. Schriml  
Associate Professor, Epidemiology & Public Health, Institute for Genome Sciences, University of Maryland School of Medicine

Suzanne Devkota  
Assistant Professor, Director Microbiome Research, F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, UCLA

A. Sloan Devlin  
Assistant Professor, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School

Aleksandar D. Kostic  
Assistant Professor, Harvard Medical School, Assistant Investigator, Joslin Diabetes Center

Hyun Jung Kim  
Assistant Professor, University of Texas at Austin

Yanjiao Zhou  
Research Scientist, The Jackson Laboratory

Eric Huang  
Professor, Department of Dermatology, University of California, San Diego

Christopher Mason, PhD  
Director, MetaSUB International Consortium

A. Sloan Devlin  
Assistant Professor, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School

Jennifer Wargo  
Assoc. Professor, Surgical Oncology, MD Anderson

Jennifer M. Fettweis, PhD  
Project Director, Vaginal Human Microbiome Project

AJ Prussin, PhD  
Charles E. Via, Jr. Department of Civil and Environmental Engineering, Virginia Tech

Stacy A. Kahn, MD  
Director FMT Program, Dept. Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital

Jessica Allegretti, MD, MPH  
Instructor, Harvard Medical School, Director, Fecal Microbiota Transplant Program, Brigham and Women’s Hospital

The earlier you book, the more you save! Visit www.terrapinn.com/microbiomeUS
The earlier you book, the more you save! Visit www.terrapinn.com/microbiomeUS

NATIONAL BODIES

Paul E. Carlson Jr.
Principal investigator, Laboratory of Mucosal Pathogens and Cellular Immunology, CBER/OVRR, U.S. Food and Drug Administration

Scott A. Jackson
Leader – Complex Microbial Systems Group Biosystems and Biomaterials Division, National Institute of Standards and Technology

Glen Satten
Senior Scientist, Centers For Disease Control and Prevention

David Butler
Director, Office of Military and Veterans Health, National Academy of Sciences (NAS)

Philip John (P.J.) Brooks
Program Director Division of Clinical Innovation, National Center for Advancing Translational Sciences (NIH)

Katherine Bowman
Senior Program Officer, National Academy of Sciences (NAS)

Scott A. Jackson
Leader – Complex Microbial Systems Group Biosystems and Biomaterials Division, National Institute of Standards and Technology

Glen Satten
Senior Scientist, Centers For Disease Control and Prevention

NATIONAL BODIES

Zachary Kurtz
Scientist, Lodo Therapeutics Corporation

Mehrdad Yazdani, Ph.D.
Machine Learning and Data Scientist, Open Medicine Institute, California Institute for Telecommunications and Information Technology, UC San Diego

Yuriy Gusev, Ph.D.
Associate Professor, Innovation Center for Biomedical Informatics (ICBI), Georgetown University Medical Center

Raja Mazumder, Ph.D.
Associate Professor of Biochemistry and Molecular Medicine, George Washington School of Medicine & Health Sciences

Jason Norman
Senior Scientist, Vedanta Biosciences

BIOINFORMATICS

Mehrdad Yazdani, Ph.D.
Machine Learning and Data Scientist, Open Medicine Institute, California Institute for Telecommunications and Information Technology, UC San Diego

Yuriy Gusev, Ph.D.
Associate Professor, Innovation Center for Biomedical Informatics (ICBI), Georgetown University Medical Center

Zachary Kurtz
Scientist, Lodo Therapeutics Corporation

Raja Mazumder, Ph.D.
Associate Professor of Biochemistry and Molecular Medicine, George Washington School of Medicine & Health Sciences
PLenary Panel  REGULATIONS IN RESPONSE TO THE MICROBIOME

- How do you work with regulators in development of Microbiome treatments?
- How do you prevent Wild West scenarios where companies are promoting their product and operating without oversight?
- From FMT, Prebiotics to Probiotics, from food supplements to traditional treatments- what protocols must be established for such a wide variety of products?
- What standards are necessary and what does solid translational evidence look like in judging the efficacy of microbial treatments?

Paul E. Carlson Jr.
Principal investigator, Laboratory of Mucosal Pathogens and Cellular Immunology
CBER/OVRR, U.S. Food and Drug Administration

Matt Henn
Senior VP, Head of Drug Discovery and Bioinformatics
Seres Therapeutics

Alex Scheeler
Senior Regulatory Affairs Associate
OpenBiome

Kathleen Basmadjian
Senior Director, Global Regulatory Policy & Intelligence, Global Regulatory Affairs
Janssen R&D
PANEL

CUTTING THROUGH THE CONFUSION OF BIOINFORMATICS

- Why do our models seem to break down when ecology meets the worlds of statistics and medicine?
- How do we continue to identify stable sub communities?
- What bacterial interactions can we look to outside of our immediate field?

MODERATOR
Zachary Kurtz
Scientist
Lodo Therapeutics

Jim Brown
Director, Computational Biology, Senior Fellow
GlaxoSmithKline

Raja Mazumder
Associate Professor of Biochemistry and Molecular Medicine
George Washington School of Medicine & Health Sciences

Jason Norman
Senior Scientist
Vedanta Biosciences
### Chairperson’s Opening Remarks

08:50

### KEYNOTE ADDRESS

09:00

**The new paradigm of treatment - understanding the relationship between ecology and medicine in unlocking the potential of the microbiome**

- What is the current state of the field and how have new techniques in molecular biology enabled us to probe the microbiome and better understand its diversity and biological significance?
- When dealing with living organisms- How does microbial ecology differ from classical drug therapies, and classical medical statistics?
- What areas have we seen greatest progress and how do we avoid overselling microbiome potential and current state before we have solid evidence of translational capacity?

*Jack Gilbert, Faculty Director, The Microbiome Center The University of Chicago*

### Speed Networking

10:00

### Networking coffee break

10:20

### TRACK I: SCIENTIFIC

#### INFECTIONS AND ANTIBIOTICS

11:00

**Re-assessing ethical issues in Microbiome research and medicine**

- How does the clinical approach change when patients can cheaply sequence their microbiome?
- Studies to advance personalized medicine will require broad public participation to provide sufficient material for biobanks.
- What implications does Microbiome Research have on our social and legal systems?

*Andreas Kogelnik, Founder and CEO, Open Medicine Institute*

11:20

**Bugs as drugs for the skin: novel microbiome-based strategies for skin diseases**

- The skin microbiome is often overlooked yet it plays a critical role in human health
- How are fluctuations in the skin microbiome associated with numerous diseases?
- Skin models in vitro and in vivo are imperfect in recapitulating the skin microbiome
- What novel strategies focused on the skin microbiome have shown promise in altering skin disease?

*Travis Whitfill, Co-Founder, Azitra*

### TRACK II: COMMERCIAL

#### CLINICAL TRIAL AND REGULATORY

11:00

**FDA update**

Points to consider Microbiome treatment development

- Understanding current guidelines for living biological samples.
- How are we addressing current challenges in developing microbial treatments?
- Regulatory implications of *C. Difficile*- microbiome- Host interactions.

*Paul E. Carlson Jr., Principal investigator, Laboratory of Mucosal Pathogens and Cellular Immunology, CBER/OVRR, U.S. Food and Drug Administration*

11:20

**Clinical innovations in Microbiome: From wellness to treatment**

- The proper regulation of Microbiome is essential if the field is to be taken seriously as a viable treatment for diseases.
- What can we learn from proper design of clinical trials?
- How do we move away from the wild west like scene of dietary supplements?

*PJ Brooks, Program Director, Director of Clinical Innovation, National Center for Advancing Translational Sciences (NIH)*

11:40

**Skin Microbiome Editing**

- Dr. Huang’s lab has established a Skin Probiotic Bank.
- How do you develop various carbohydrate-polymer conjugates as selective fermentation inducers (SFIs) for editing skin microbiome?
- Furthermore, fifty skin probiotic bacteria can be used as probiotics for treatment of more than twenty skin diseases including acne vulgaris.

*Eric Huang, Professor, Department of Dermatology, University of California, San Diego*

#### The great potential and limitations of the mouse model

- With mouse models being standard models why do we often see such varying results?
- What microbiome communities are essential to lab mice?
- Can cohabiting mice with common mice offer stronger research subjects that better replicate the human immune system?

*Aleksandar D. Kostic, Assistant Professor, Harvard Medical School, Assistant Investigator, Joslin Diabetes Center*
### ROUNDTABLES

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Institution</th>
</tr>
</thead>
</table>
| 12:00      | Loss of Food Species
How is a reduction in Dietary diversity affecting our Microbiome? | Zachary Kurtz, Scientist, Lodo Therapeutics Corporation   |
|            | FMT
Current state and future potential                                  | Jessica Allegretti, Instructor, Harvard Medical School,    |
|            |                                                                       | Director, Fecal Microbiota Transplant Program, Brigham and |
|            |                                                                       | Women’s Hospital                                          |
|            | Bioinformatics
Utilizing and translating microbiome data sets                  |                                                          |
|            | Mouse Model
Potential and Limitations of mouse models                          | Aleksandar D. Kostic, Assistant Professor, Harvard Medical |
|            |                                                                       | School, Assistant Investigator, Joslin Diabetes Center    |
|            | Microbiome of the built environment
From research to application                                             | Lynn M. Schriml, Associate Professor, Epidemiology &      |
|            |                                                                       | Public Health, Institute for Genome Sciences, University of|
|            |                                                                       | Maryland School of Medicine                               |
| 12:40      | Networking lunch                                                      |                                                          |

If you are interested in sponsoring the moderation of a roundtable contact Salvatore Manzo at +1 646 619 1798 or salvatore.manzo@terrapinn.com

The earlier you book, the more you save! Visit www.terrapinn.com/microbiomeUS
2:00  Panel  Cutting through the confusion of Bioinformatics
• Why do our models seem to break down when ecology meets the worlds of statistics and medicine?
• How do we continue to identify the stable sub communities?
• What bacterial interactions can we look to outside of our immediate field?

Moderator
Zachary Kurtz Scientist, Lodo Therapeutics Corporation
Jim Brown, Director, Computational Biology, Senior Fellow, GlaxoSmithKline
Raja Mazumder, Associate Professor of Biochemistry and Molecular Medicine, George Washington School of Medicine & Health Sciences
Jason Norman, Senior Scientist, Vedanta Biosciences

2:20  Teaching Computers to recognize the sick gut
• What advantages do Machine learning offer us in Microbiome?
• How do you train systems to identify Healthy bacteria communities?
• What relationships are we looking for as we are rarely looking at just one molecule?

Mehrdad Yazdani, Machine Learning and Data Scientist, Open Medicine Institute, UC San Diego

2:40  C-section delivery and the criticality of Vaginal microbiome in allergies, and immune disorder
• How influential is early microbiota on later life events?
• Can we re-introduce the vaginal microbiome to C-section babies to avoid averse immune disorders, and allergies?
• What effects are we seeing over the long term in c-section children?
• Could this be the new and healthier standard for delivering newborns?

Jose C. Clemente, Assistant Professor, Department of Genetics and Genomic Sciences and the Immunology Institute, Icahn School of Medicine at Mount Sinai

3:00  Gut-on-a-Chip, changing the future of PV for the Microbiome
• A microphysiological human intestine model
• In vitro host-gut microbiome ecosystem and long-term maintenance
• Modeling intestinal diseases to validate therapeutic interventions

Hyun Jung Kim, Assistant Professor, University of Texas at Austin

3:00  Personalized Nutrition for the Microbiome
• With microbiome and nutrition becoming more synergistic how close are we to moving prediction and prevention with dietary changes?
• Looking at current data- How can we interpret the current state of individualized microbiome responses to various foods and healthy and diseased states?
• What does this mean for the future of food and for the treatment landscape?

Suzanne Devkota, Assistant Professor, Director Microbiome Research, F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Assistant Professor-in-Residence, David Geffen School of Medicine, UCLA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:20</td>
<td><strong>A chemical understanding of the Gut Microbiome</strong></td>
<td>A. Sloan Devlin, Assistant Professor, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School</td>
</tr>
<tr>
<td></td>
<td>• Uncovering how and why bacteria metabolize bile acids?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• How do these bile acids influence biological processes?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• How can we make use of this to better monitor and alter bacterial metabolism in vivo?</td>
<td></td>
</tr>
<tr>
<td>3:40</td>
<td><strong>The Elite Athlete Microbiome: What makes top Athletes so unique?</strong></td>
<td>Jonathan Scheiman, Co-Founder CEO, FitBiomics</td>
</tr>
<tr>
<td></td>
<td>• How Can we utilize next-generation sequencing to understand what makes elite athletes unique?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• What changes are we seeing pre and post sport activity?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• What does this mean in the next generation of athletes?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Are we seeing key markers for endurance, fatigue and recovery?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• How can this be used to aid the wider population?</td>
<td></td>
</tr>
<tr>
<td>4:00</td>
<td><strong>Networking coffee break</strong></td>
<td></td>
</tr>
<tr>
<td>4:40</td>
<td><strong>KEYNOTE ADDRESS</strong></td>
<td>Cosmas Giallourakis, Director R&amp;D, Takeda</td>
</tr>
<tr>
<td></td>
<td>Identify partnerships in the emerging microbiome Industry</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• How and why is each party involved in a transaction? How have you defined critical roles of support?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• How do the therapeutic area and stage of development affect the financial valuation?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• How do small and large companies bridge the gap between approaches to asset and financial valuation?</td>
<td></td>
</tr>
</tbody>
</table>

**Harnessing nature to help farmers sustainably feed the planet**

• How do we increase agricultural activity while not relying on technology of the high yields gains of the past?
• What is being done to isolate the endophytes of various plants and how can this improve drought resistance, nutrient absorption, etc?
• What real-life examples have we seen of the benefits of these enhanced food and crops?

**Barry Goldman, Vice President, Discovery, Indigo Agriculture**

| 5:00  | **KEYNOTE ADDRESS**                                                                                                      | Nikola Trbovic, Director, R&D Technology Strategy, Pfizer |
|       | A large pharma perspective on the microbiome                                                                            |                                                      |
|       | • How does Pfizer evaluate opportunities in the microbiome?                                                             |                                                      |
|       | • What developments in the field is Pfizer monitoring most closely?                                                     |                                                      |
|       | • What capabilities does Pfizer consider most valuable in biotech partners?                                             |                                                      |

**Nikola Trbovic, Director, R&D Technology Strategy, Pfizer**

| 5:20  | **Chairperson's Closing Remarks**                                                                                       |                                                      |
| 5:30  | **Drinks reception**                                                                                                   |                                                      |
DAY 2 WEDNESDAY 8 NOVEMBER 2017

09:00 KEYNOTE ADDRESS
From discovery to clinical – SYN-004 (ribaxamase) protects the gut microbiome from antibiotic-mediated damage
- Importance of maintaining a healthy gut microbiome — when faced with the threat of antibiotics, strategies include to protect, repair, or replace the gut microbiota.
- Discussion of ribaxamase as a means to protect the microbiome from beta lactam antibiotics.
- Ramifications beyond the individual.

Michael Kaleko, Senior Vice President, Research & Development, Synthetic Biologics

09:20 KEYNOTE PANEL
Regulations in response to the Microbiome
- How do you work with regulators in development of Microbiome treatments?
- How do you prevent Wild West scenarios where many companies are promoting their product and operating without oversight?
- From FMT, Prebiotics to Probiotics, from food supplements to traditional treatments- what protocols must be established for such a wide variety of products?
- What standards are necessary and what does solid translational evidence look like in judging the efficacy of microbial treatments?

Paul E. Carlson Jr., Principal investigator, Laboratory of Mucosal Pathogens and Cellular Immunology, CBER/OVRR, U.S. Food and Drug Administration
Matt Henn, Senior VP, Head of Drug Discovery and Bioinformatics, Seres Therapeutics
Alex Scheeler, Senior Regulatory Affairs Associate, OpenBiome
Kathleen Basmadjian, Senior Director, Global Regulatory Policy & Intelligence, Global Regulatory Affairs, Janssen R&D

10:00 If your company is a leader in Microbiome R&D then you can sponsor this session by contacting Salvatore Manzo at +1 646 619 1798 or salvatore.manzo@terrapinn.com

10:20 Speed Networking

10:40 Networking coffee break

11:20 The vaginal microbiome during pregnancy and the postpartum period
- What differences do we see in the vaginal microbiome throughout pregnancy?
- Does the composition and structure of the pregnancy vaginal microbiome influence susceptibility to adverse pregnancy outcomes?
- Why are there such large differences across women of different ethnicities?

Marina R. Walther-Antonio, Assistant Professor of Surgery, Mayo Clinic

TRACK I: SCIENTIFIC

WOMEN’S HEALTH

TRACK II: COMMERCIAL

COMMERCIALIZATION INVESTMENT LANDSCAPE

PANEL
Securing funding from multiple sources – how to continuously show value to pharma, venture capital, and grant programs
Micah Mackison, VP Corporate Development and Strategy, Assembly Biosciences
Rodolphe Clerval, Chief Business Officer, Enterome Bioscience
Henry Rath, VP Business Development, Seres Therapeutics
The functionality of the vaginal microbiome
- Examining the roles of the women’s urogenital conditions, physiological states, environmental factors and host genetic components to the structure and composition of the vaginal microbiome
- Investigating the role of the vaginal microbiome in pregnancy and the peripartum period in full-term and preterm pregnancies
- Characterizing and comparing the genomes of previously uncharacterized species of importance to women’s reproductive health
- What states of the vaginal microbiome are protective?

Jennifer M. Fettweis, Project Director, Vaginal Human Microbiome Project, Virginia Commonwealth University

The Critical role of the Early Microbiome in Childhood health and development
- Commense is developing approaches to guide the priming, seeding, and maintaining of the microbiome in infants and children.
- Can nurturing a healthy microbiome early in life represent a novel strategy to significantly reduce the impact of diseases?
- What insights can we gain from natural exposures to beneficial microbes?
- How can physicians, and product developers take advantage of these finds to develop a novel category of products to address critical unmet needs in pediatric populations?

James Mutamba, Co-Founder, Commense Health

Accelerating and optimizing phage therapy in human health to enhance the microbiome
- How is the rebirth of American Phage therapy able to influence the Microbiome?
- How is Epibiome able to produce fully automated viral and bacterial identification for phage cocktails?
- What are the opportunities in not just human, but food, and animal?

Nick Conley, President & CEO, Epibiome
The Therapeutic Landscape for Atopy and Asthma

- Focusing on the design of a mixed-species therapeutic microbial consortium to treat airway inflammation.

- How do you leverage multi-scale next-generation microbiome analyses to develop and test microbial-based therapeutics for induction and maintenance of immune tolerance?

- How can we use the microbiome to drive patient stratification and tailored microbial therapeutics?

Nikole Kimes, Founder, Vice President, Siolta Therapeutics

SKIN, ORAL, AND LUNG

- The microbiota modulates gut physiology and behavioral abnormalities associated with autism
  - How can observation of Gut Brain Axis help inform us of ASD?
  - Can extended-duration treatment protocol be a promising approach to alter the gut microbiome and virome?
  - Does reversal of Autism like symptoms in mice mean Microbiome transplant treatments?

Elaine Hsiao, Principal Investigator, Hsiao Lab, UCLA

- The Microbiome and Multiple Sclerosis
  - How can the Gut Microbiome shape host immunity and communicate with CNS via Gut Brain Axis?
  - What microbes, genes and metabolites have been identified that protect from autoimmunity?
  - How does the gut microbiome affect treatment efficiency of MS drugs in Mouse models?

Yanjiao Zhou, Research Scientist, The Jackson Laboratory

- The extreme personalization potential in microbiome and Immunotherapy
  - How are the trillions of bacteria in our bodies creating unique individual makeups?
  - Are drug immunotherapies reacting to the microflora of our gut?
  - What promising efforts have been made to align with immunotherapy?

Jennifer Wargo, Assoc. Professor, Surgical Oncology, MD Anderson

- Microbiome of the Built Environment: From Research to Application
  - How can we examine the formation and function of microbial communities in built environments?
  - What are the impacts of such communities on human health?
  - How do humans shape complex indoor microbiomes?

Lynn M. Schriml, Associate Professor, Epidemiology & Public Health, Institute for Genome Sciences, University of Maryland School of Medicine

- The Metagenomic and Metadesign of Subways and Urban Biomes
  - How can we improve city utilization and planning through the detection, measurement, and design of metagenomics within urban environments?
  - How can these baseline profiles be used to identify potential bio-threats, and provide an additional level of data, that can even aid in Smart City Capabilities?

Christopher Mason, Director, MetaSUB International Consortium

Architectural design for health and wellness

- What does it mean when structures are not just environmentally sustainable but actually benefit the health of their inhabitants and communities?
- How do building materials and finishes relate to human and environmental health?
- How can you scale “Restorative design” from the individual, to building, to community, to global?

If your company provides solution for “microbiome-conscious” built-in environment than you can sponsor this session by contacting Salvatore Manzo at +1 646 619 1798 or salvatore.manzo@terrapinn.com
As Microbiome treatment moves from buzzword to reality, discovery, development, and commercialization are becoming more critical. Coupled with this shift is a flood of capital into new and established biopharma and diagnostics companies, as investors and venture capitalists become an increasingly important source of funding for the most important breakthroughs in Microbiome.

The lack of a platform for these investors and their potential clients has contributed to the launch of Pitch & Partner at the World Microbiome Congress Americas 2017. Pitch & Partner will enable new and old pharma and biotech companies to pitch their microbiome innovations in front of an audience of VCs and investors, as well as exposing them to successful case studies of past funding ventures.

The list of investors and investees will be released shortly, but we can reveal that the track will open with an exclusive panel session on how to secure funding in today’s crowded pharma environment.

---

**PANEL SESSION**

Securing funding from multiple sources – how to continuously show value to pharma, venture capital, and grant programs

---

**Micah Mackison**  
VP Corporate Development & Strategy  
Assembly Biosciences

**Rodolphe Clerval**  
Chief Business Officer  
Enterome Bioscience

**Henry Rath**  
VP Business Development  
Seres Therapeutics
Making the Most of the Event with Jujama

Jujama is our full service app that allows you to manage your time efficiently and effectively at the event, while ensuring you meet all the right people.

You can use the app to set meetings, explore the agenda, familiarize yourself with speakers and exhibitors and much, much more. Log into your profile, update your details and get started. It’s that simple!

Networking with Jujama is available 24/7, enabling you to plan and get the most out of the event well in advance. Accessible via numerous devices, you can:

- Review the latest exhibitor list and see where booths are on the floorplan
- Contribute to specific groups and start conversations long before the event
- Share relevant content with your social networks

As an event attendee, you’ll get access to your FREE event management profile and will get personalized login details to use the app.

Business Matching at the event goes live four weeks before the show.

Any queries contact jessie.sampson@terrapinn.com

Note: Jujama respects your privacy and assures you that all of your personal contact information will be kept confidential. Rest assured that no contact information will be shared via our platform.

Event Partners
10 reasons to attend

1. The only microbiome conference in North America focusing on both the scientific and commercial opportunities in the field.

2. Keynote case studies from microbiome game-changers such as Jack Gilbert whose pioneering metagenomics work and extensive study of the dynamics of thousands of microbial environments has shaped the modern Microbiome field.

3. Hear from the FDA on the many hurdles to consider when developing microbiome-based treatments.

4. Cut through the confusion on bioinformatics with an exclusive panel and roundtable hosted by Zach Kurtz, with leaders from George Washington School of Medicine & Health Sciences, UC San Diego, Georgetown University Medical Center and GlaxoSmithKline.

5. Navigate the Wild West of microbiome regulations: with a one of a kind panel of regulatory experts including the FDA, OpenBiome, Seres Therapeutics and Janssen’s Senior Director of Global Regulatory Affairs.

6. Go beyond the gut with groundbreaking case studies on skin, brain, oral and vaginal microbiome for a full view of the clinical opportunities in the field.

7. Find out how to navigate the risky world of funding as the leading biotechs of Assembly Bio Sciences, Enterome and SeresTherapeutics show attendees how to demonstrate value to pharma, venture capitalists and grant programs.

8. Preview the game-changers of the future with case studies on everything from the unique athlete microbiome (FitBiomics), to the game changing “Gut on a Chip.”

9. Witness innovation in the making with a Pitch & Partner breakout stream, where biotechs will highlight the opportunities of the future and investors will make them happen.

10. You will have full access to the co-located World Precision Medicine Congress in Washington D.C., meaning a 2-for-1 opportunity to usher your work into the next generation of personalized medicine, and health!
Register now

The earlier you book, the more you save! Reserve your spot today!

For the latest price see www.terrapinn.com/microbiomeUS

<table>
<thead>
<tr>
<th>2 DAY CONFERENCE PASS</th>
<th>TIER 1</th>
<th>TIER 2</th>
<th>TIER 3</th>
<th>TIER 4</th>
<th>FINAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>18 AUG</td>
<td>9 SEPT</td>
<td>29 SEPT</td>
<td>20 OCT</td>
<td></td>
</tr>
<tr>
<td>GROUP OF 3+</td>
<td></td>
<td></td>
<td>$1,680</td>
<td>$1,880</td>
<td>$1,980</td>
</tr>
</tbody>
</table>

BOOK NOW

Register at  www.terrapinn.com/microbiomeUS

Or call +1 212 379 6320

BRING YOUR TEAM

With two days packed full of great content and networking opportunities, you can’t possibly cover it all alone!

Bring your team and get an extra discount. Call +1 212 379 6320